Safety and Efficacy of Recombinant Human Brain Natriuretic Peptide in the Treatment of Decompensated Heart Failure of Coronary Heart Disease
Objective To study the safety and efficacy of recombinant human brain natriuretic peptide(rh-BNP)in the treatment of decompensated heart failure(DHF)of coronary heart disease.Methods From December 2020 to December 2022,60 patients with DHF of coronary heart disease admitted to Pingxiang Third People's Hospital were selected and divided into control group(30 patients)and observation group(30 patients)according to the random number table method.The control group was treated with routine treatment,and the observation group was treated with rh-BNP on the basis of routine treatment.The clinical efficacy,physical signs[heart rate(HR),mean arterial pressure(MAP),24-h urine volume],cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),cardiac output(CO)],severity of disease[Seattle angina questionnaire(SAQ),heart failure symptom status questionnaire(SSQ-HF)]and adverse reactions were compared between the two groups.Results The effective rate of treatment in the observation group(90.00％)was higher than that in the control group(73.33％)(P＜0.05).After treatment,HR and MAP in the two groups were lower than those before treatment,and 24 h urine volume was more than that before treatment,HR and MAP in the observation group were lower than those in the control group,and 24 h urine volume was more than that in the control group(P＜0.05).After treatment,LVEF and CO in the two groups were higher than those before treatment,LVEDD was lower than that before treatment,and LVEF and CO in the observation group were higher than those in the control group,LVEDD was lower than that in the control group(P＜0.05).After treatment,the SAQ score of the two groups was higher than that before treatment,and the SSQ-HF score was lower than that before treatment,while the SAQ score of the observation group was higher than that of the control group,and the SSQ-HF score was lower than that of the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).Conclusion rh-BNP has high efficacy and safety in the treatment of DHF in coronary heart disease.Meanwhile,it can regulate the signs of patients,improve their cardiac function,promote the prognosis of the disease,and do not increase adverse reactions.
国家科技期刊平台
NSTL
万方数据
维普
